Antimalarial activity of crambescidin 800 and synthetic analogues against liver and blood stage of Plasmodium sp.

Marine Science Institute, University of the Philippines, Diliman 1101, Quezon City, Philippines.
The Journal of Antibiotics (Impact Factor: 2.19). 10/2006; 59(9):583-90. DOI: 10.1038/ja.2006.78
Source: PubMed

ABSTRACT Structural features associated with the antimalarial activity of the marine natural product crambescidin 800 were studied using synthetic analogues of the related compound ptilomycalin A. The study suggests that the guanidine moiety is cytotoxic, whereas the spermidine-containing aliphatic chain increases activity. The most active analogue, compound 11, had in vitro activity against Plasmodium falciparum strain 3D7 (IC50=490 nM) that was stronger than the in vitro activity against murine L5178Y cells (IC50 = 8.5-59 microM). In vitro growth inhibition of liver stages of P. yoelii yoelii in mouse hepatocytes was observed (IC50 = 9.2 microM). The compound did not significantly prolong median survival time after a single subcutaneous administration of 80 mg/kg in P. berghei-infected mice. Compound 11 did not cause DNA fragmentation in an in vitro micronucleus assay.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Organic guanidine compounds are reviewed, with emphasis on natural products isolation, identification, synthesis and biological activities. The literature survey includes purely synthetic guanidine derivatives, guanidine alkaloids and non-ribosomal peptides from bacteria and cyanobacteria, as well as related compounds isolated from marine and terrestrial invertebrates and higher plants.
    Natural Product Reports 11/2008; 25(5):919-54. · 10.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review focuses on six important parasitic diseases that adversely affect the health and lives of over one billion people worldwide. In light of the global human impact of these neglected tropical diseases (NTDs), several initiatives and campaigns have been mounted to eradicate these infections once and for all. Currently available therapeutics summarized herein are either ineffective and/or have severe and deleterious side effects. Resistant strains continue to emerge and there is an overall unmet and urgent need for new antiparasitic drugs. Marine-derived small molecules (MDSMs) from invertebrates comprise an extremely diverse and promising source of compounds from a wide variety of structural classes. New discoveries of marine natural product privileged structures and compound classes that are being made via natural product library screening using whole cell in vitro assays are highlighted. It is striking to note that for the first time in history the entire genomes of all six parasites have been sequenced and additional transcriptome and proteomic analyses are available. Furthermore, open and shared, publicly available databases of the genome sequences, compounds, screening assays, and druggable molecular targets are being used by the worldwide research community. A combined assessment of all of the above factors, especially of current discoveries in marine natural products, implies a brighter future with more effective, affordable, and benign antiparasitic therapeutics.
    Current opinion in biotechnology 10/2010; 21(6):808-18. · 7.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thesis (M.S.)--University of New Mexico, 1992. Includes bibliographical references (leaf 151).

Full-text (2 Sources)

Available from
May 26, 2014